Overly Aggressive Prialt Dose Data Are Not Surrogate Endpoints, FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Data from failed dosing protocols do not constitute surrogate endpoints, FDA informed Elan in rejecting the company’s bid for accelerated approval of Prialt.